MSRB1P1: A Potential Drug Target and Biomarker for Methionine Sulfoxide Reductase B1 Pseudogene 1

Target Name: MSRB1P1

NCBI ID: G441849

MSRB1P1

Other Name(s): methionine sulfoxide reductase B1 pseudogene 1 | Methionine sulfoxide reductase B1 pseudogene 1

MSRB1P1: A Potential Drug Target and Biomarker for Methionine Sulfoxide Reductase B1 Pseudogene 1

Methionine sulfoxide reductase B1 pseudogene 1 (MSRB1P1) is a gene that encodes a protein involved in the detoxification of methionine sulfoxide (MSO), a toxic metabolite generated by the amino acid methionine. MSO is a potent neurotoxin that can cause various neurological disorders, including neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Therefore, targeting MSRB1P1 and modulating its activity may provide new therapeutic approaches for the treatment of these debilitating conditions.

The MSRB1P1 gene

MSRB1P1 is a member of the superfamily of C2H2-containing N-terminal hydrolases, which are involved in the detoxification of various metabolites. The MSRB1P1 gene encodes a 164- amino acid protein that contains a distinct N-terminal region with a putative cytoplasmic domain, a transmembrane region, and a C-terminal region with a conserved hypothetical putative cytoplasmic domain (HPD).

Function and localization

MSRB1P1 is involved in the detoxification of MSO, which is a potent neurotoxin generated by the amino acid methionine. MSO is a highly reactive molecule that can form various metabolites, including 2-oxo-MSO, which is a toxic metabolite that can cause neurotoxicity and contribute to the development of neurodegenerative diseases.

The MSRB1P1 gene has been shown to be expressed in various tissues, including brain, spleen, and heart. Localization studies have shown that MSRB1P1 is predominantly expressed in the brain, where it is enriched in the peri-synaptic zone, a region of the brain that is involved in neurotransmitter release and signaling.

Drug targeting

The MSRB1P1 gene has potential as a drug target for the treatment of neurodegenerative diseases. One approach to targeting MSRB1P1 is to develop small molecules that can inhibit the activity of MSRB1P1. Such compounds could be used to treat neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

Biomarker potential

MSRB1P1 has also been considered as a potential biomarker for neurodegenerative diseases. The level of MSRB1P1 expression is often reduced in neurodegenerative diseases, and this reduction in expression may be an indicator of the severity of the disease. Therefore, measuring the level of MSRB1P1 expression may provide a diagnostic tool for neurodegenerative diseases and monitor the effectiveness of therapeutic interventions.

Conclusion

In conclusion, MSRB1P1 is a gene that encodes a protein involved in the detoxification of MSO, a potent neurotoxin that can cause various neurological disorders. The MSRB1P1 gene has potential as a drug target for the treatment of neurodegenerative diseases and as a biomarker for monitoring the effectiveness of therapeutic interventions. Further research is needed to fully understand the role of MSRB1P1 in neurodegenerative diseases and to develop effective therapeutic approaches.

Protein Name: Methionine Sulfoxide Reductase B1 Pseudogene 1

The "MSRB1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MSRB1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets